Cormedix (CRMD) Given a $2.00 Price Target at HC Wainwright

HC Wainwright set a $2.00 price objective on Cormedix (NYSEAMERICAN:CRMD) in a report published on Wednesday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

Separately, Zacks Investment Research lowered shares of Cormedix from a buy rating to a sell rating in a research report on Wednesday, April 4th.

CRMD stock opened at $0.18 on Wednesday. Cormedix has a one year low of $0.17 and a one year high of $0.77.

Cormedix (NYSEAMERICAN:CRMD) last released its quarterly earnings results on Monday, March 19th. The biotechnology company reported ($0.15) EPS for the quarter. The firm had revenue of $0.09 million for the quarter. Cormedix had a negative net margin of 16,300.49% and a negative return on equity of 318.95%.

An institutional investor recently raised its position in Cormedix stock. Virtu Financial LLC increased its holdings in Cormedix (NYSEAMERICAN:CRMD) by 126.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 226,748 shares of the biotechnology company’s stock after buying an additional 126,610 shares during the quarter. Virtu Financial LLC owned about 0.34% of Cormedix worth $114,000 at the end of the most recent reporting period.

Cormedix Company Profile

CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.

Receive News & Ratings for Cormedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cormedix and related companies with's FREE daily email newsletter.

Leave a Reply